Stable schizophrenia patients switched to paliperidone palmitate 3-monthly formulation in real life: functioning and resource use

被引：1

作者：

Garcia-Portilla, P. ^{[1
]}

Llorca, P. M. ^{[2
]}

Maina, G. ^{[3
]}

Bozikas, V. P. ^{[4
]}

Devrimci-Ozguven, H. ^{[5
]}

Kim, S. W. ^{[6
]}

Bergmans, P. ^{[7
]}

Usankova, I. ^{[8
]}

Cherubin, P. ^{[9
]}

Pungor, K. ^{[10
]}

机构：

[1] Univ Oviedo, Cibersam, Oviedo, Spain

[2] CHR Univ Clermont Ferrand, Pole Psychiat, Clermont Ferrand, France

[3] Univ Torino, SCDU Psichiat, AOU San Luigi Gonzaga, Turin, Italy

[4] Aristotle Univ Thessaloniki, Dept Psychiat, Sch Med, Thessaloniki, Greece

[5] Ankara Univ, Sch Med, Dept Psychiat, Ankara, Turkey

[6] Chonnam Natl Univ, Med Sch, Gwangju, South Korea

[7] Janssen Cilag Biostat & Programming, Biostat & Programming, Breda, Netherlands

[8] Johnson & Johnson, Med Affairs Org, Moscow, Russia

[9] Janssen Cilag, EMEA Med Affairs, Issy Les Moulineaux, France

[10] Janssen Cilag, EMEA Med Affairs, Dusseldorf, Germany

来源：

EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2019年 / 29卷

关键词：

REMISSION;

D O I：

10.1016/j.euroneuro.2018.11.383

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P.272

引用

页码：S238 / S239

页数：2

共 50 条

[1] Stable schizophrenia patients switched to paliperidone palmitate 3-monthly formulation in real life: impact on caregiver burden
Maina, G.
Garcia-Portilla, M. P.
Llorca, P. M.
Bozikas, V. P.
Devrimci-Ozguven, H.
Kim, S. W.
Bergmans, P.
Strulev, V.
Cherubin, P.
Pungor, K.
EUROPEAN PSYCHIATRY, 2019, 56 : S262 - S262
[2] Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia
Yvette N. Lamb
Gillian M. Keating
Drugs, 2016, 76 : 1559 - 1566
[3] Paliperidone Palmitate Intramuscular 3-Monthly Formulation: A Review in Schizophrenia
Lamb, Yvette N.
Keating, Gillian M.
DRUGS, 2016, 76 (16) : 1559 - 1566
[4] Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes
Pungor, Katalin
Bozikas, Vasilis P.
Emsley, Robin
Llorca, Pierre-Michel
Gopal, Srihari
Mathews, Maju
Wooller, Annette
Bergmans, Paul
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2020, 10
[5] Clinical effectiveness of paliperidone palmitate intramuscular 3-monthly formulation in patients with schizophrenia: A case series
Porras Segovia, A.
Guerrero, M.
Carrillo de Albornoz, C.
Gutierrez-Rojas, L.
EUROPEAN PSYCHIATRY, 2018, 48 : S533 - S533
[6] SYMPTOMATIC REMISSION WITH PALIPERIDONE PALMITATE 3-MONTHLY FORMULATION IN SCHIZOPHRENIA PATIENTS IN A CLINICAL PRACTICE SETTING
Garcia-Portilla, M. P.
Llorca, P. M.
Maina, G.
Bozikas, V. P.
Devrimci-Ozguven, H.
Kim, S. W.
Bergmans, P.
Usankova, I.
Cherubin, P.
Najarian, Dean
Pungor, K.
SCHIZOPHRENIA BULLETIN, 2019, 45 : S295 - S296
[7] Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation
Corbeil, Olivier
Essiambre, Anne-Marie
Bechard, Laurent
Roy, Audrey-Anne
Huot-Lavoie, Maxime
Brodeur, Sebastien
Chandrasena, Ranjith
Theriault, Chantale
Crocker, Candice
Melun, Jean-Pierre
Tibbo, Phil
Demers, Marie-France
Roy, Marc-Andre
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2022, 12
[8] Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
Mathews, Maju
Gopal, Srihari
Nuamah, Isaac
Hargarter, Ludger
Savitz, Adam J.
Kim, Edward
Tan, Wilson
Soares, Bernardo
Correll, Christoph U.
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 1365 - 1379
[9] Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate
Lencer, Rebekka
Paz Garcia-Portilla, Maria
Bergmans, Paul
Gopal, Srihari
Mathews, Maju
Wooller, Annette
Pungor, Katalin
COMPREHENSIVE PSYCHIATRY, 2021, 107
[10] Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate
Pai, Nagesh
Warden, Matthew
AUSTRALASIAN PSYCHIATRY, 2018, 26 (06) : 628 - 634

← 1 2 3 4 5 →